EHP-101 | CAS#1818428-24-8 | VCE-004.8 lipidic formulation

MedKoo Cat#: 463862 | Name: EHP-101

Description:

WARNING: This product is for research use only, not for human or veterinary use.

EHP-101 is an oral lipidic formulation of VCE-004.8 that has shown efficacy in several preclinical models of autoimmune, inflammatory, fibrotic, and neurodegenerative diseases.

Chemical Structure

EHP-101

CAS#1818428-24-8

Theoretical Analysis

MedKoo Cat#: 463862

Name: EHP-101

CAS#: 1818428-24-8

Chemical Formula: C28H35NO3

Exact Mass: 433.2617

Molecular Weight: 433.59

Elemental Analysis: C, 77.56; H, 8.14; N, 3.23; O, 11.07

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

EHP-101; EHP101; EHP 101; VCE-004; VCE004; VCE 004; VCE-004.8; VCE004.8; VCE 004.8; etrinabdione

IUPAC/Chemical Name

(1'R,6'R)-3-(benzylamino)-6-hydroxy-3'-methyl-4-pentyl-6'-(prop-1-en-2-yl)-[1,1'-bi(cyclohexane)]-2',3,6-triene-2,5-dione

InChi Key

NTGIXJASMBWXRO-JTHBVZDNSA-N

InChi Code

InChI=1S/C28H35NO3/c1-5-6-8-13-22-25(29-17-20-11-9-7-10-12-20)27(31)24(28(32)26(22)30)23-16-19(4)14-15-21(23)18(2)3/h7,9-12,16,21,23,29,32H,2,5-6,8,13-15,17H2,1,3-4H3/t21-,23+/m0/s1

SMILES Code

CCCCCC1=C(C(C([C@@H]2C=C(CC[C@H]2C(C)=C)C)=C(C1=O)O)=O)NCc3ccccc3

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 433.59 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Navarrete C, García-Martin A, Garrido-Rodríguez M, Mestre L, Feliú A, Guaza C, Calzado MA, Muñoz E. Effects of EHP-101 on inflammation and remyelination in murine models of Multiple sclerosis. Neurobiol Dis. 2020 Sep;143:104994. doi: 10.1016/j.nbd.2020.104994. Epub 2020 Jun 26. PMID: 32599064. 2: García-Martín A, Garrido-Rodríguez M, Navarrete C, Caprioglio D, Palomares B, DeMesa J, Rollland A, Appendino G, Muñoz E. Cannabinoid derivatives acting as dual PPARγ/CB2 agonists as therapeutic agents for systemic sclerosis. Biochem Pharmacol. 2019 May;163:321-334. doi: 10.1016/j.bcp.2019.02.029. Epub 2019 Feb 27. PMID: 30825431. 3: García-Martín A, Garrido-Rodríguez M, Navarrete C, Del Río C, Bellido ML, Appendino G, Calzado MA, Muñoz E. EHP-101, an oral formulation of the cannabidiol aminoquinone VCE-004.8, alleviates bleomycin-induced skin and lung fibrosis. Biochem Pharmacol. 2018 Nov;157:304-313. doi: 10.1016/j.bcp.2018.07.047. Epub 2018 Aug 2. PMID: 30076848.